US · NUVL
Nuvalent, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02142
- Website
- nuvalent.com
Price · as of 2025-12-31
$99.04
Market cap 7.41B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $15.50 | ||||
| 2022 | $26.50 | ||||
| 2023 | $84.39 | ||||
| 2024 | $71.07 | ||||
| 2025 | $101.29 |
AI valuation
Our deep-learning model estimates Nuvalent, Inc.'s (NUVL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $99.04
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NUVL | Nuvalent, Inc. | $99.04 | 7.41B | — | — | — | — | -17.31 | 5.90 | — | -571.33 | -35.43 | 5.90 | 0.00% | — | — | -36.70% | 481.41% | -33.30% | 0.00 | — | 15.27 | 15.05 | 24.96 | 4885.00% | — | 4871.00% | -3.74% | -3.02 | 319.78% | 0.00% | 0.00% | 1.58% | -14.46 | -21.77 | — | 26.05 |
| ABVX | Abivax S.A. | $121.28 | 7.95B | -67% | -97% | — | — | -2.42 | 10.50 | 39.48 | -2.21 | — | 27.39 | 100.00% | -1602.89% | -1633.08% | -148.98% | 2618.19% | -66.22% | 2.40 | -41.33 | 1.84 | 1.72 | 0.27 | -1837.00% | 13354.00% | 5429.00% | -36.31% | -1.66 | 2341.68% | 0.00% | 0.00% | 0.00% | -2.19 | -2.45 | 35.14 | -3.71 |
| ARWR | Arrowhead Pharmaceuticals… | $63.27 | 8.86B | +5,558% | +96,147% | -95% | — | 272.90 | 17.63 | 9.91 | 46.50 | — | 17.90 | 97.12% | 11.86% | -0.20% | 9.24% | 42.67% | 2.39% | 0.79 | 1.10 | 4.86 | 4.74 | 0.85 | -9976.00% | 2325815.00% | -12596.00% | 1.91% | 0.92 | 116.49% | 0.00% | 0.00% | 7.42% | 77.94 | 48.86 | 9.24 | 5.43 |
| AXSM | Axsome Therapeutics, Inc. | $163.89 | 8.38B | -38% | +8,512% | — | — | -45.19 | 93.74 | 12.96 | -48.76 | — | 231.63 | 92.56% | -26.51% | -28.69% | -252.11% | 574.69% | -29.11% | 2.73 | -25.81 | 1.55 | 1.44 | 0.49 | -3856.00% | 6555.00% | -2741.00% | -1.13% | -0.25 | 318.10% | 0.00% | 0.00% | 0.00% | -48.43 | -87.74 | 12.84 | 6.09 |
| CRSP | CRISPR Therapeutics AG | $60.14 | 5.77B | -40% | -46% | — | +738% | -9.40 | 2.84 | 1556.91 | -7.08 | -19.15 | 2.84 | -6537.01% | -16191.40% | -16569.77% | -30.18% | -191.73% | -25.81% | 0.21 | — | 13.32 | 13.25 | -0.07 | 4908.00% | -8997.00% | 13911.00% | -6.33% | -2.31 | -116.70% | 0.00% | 0.00% | 0.00% | -6.83 | -11.23 | 1106.51 | 8.49 |
| CYTK | Cytokinetics, Incorporate… | $62.22 | 7.61B | -4% | -61% | — | — | -9.39 | -11.18 | 83.75 | -10.03 | -38.60 | -11.18 | 100.00% | -695.44% | -891.60% | 197.47% | 179.99% | -55.55% | -1.95 | — | 4.53 | 4.36 | -0.52 | 2433.00% | 37656.00% | 3377.00% | -7.25% | -2.52 | 157.23% | 0.00% | 0.00% | 3.96% | -12.70 | -14.54 | 88.31 | -2.06 |
| JAZZ | Jazz Pharmaceuticals plc | $190.02 | 11.7B | -5% | -56% | -94% | — | -32.61 | 2.69 | 2.72 | 104.22 | — | -5.99 | 88.21% | 5.26% | -8.35% | -8.47% | 2.26% | -3.01% | 0.25 | 1.15 | 1.86 | 0.99 | -2.87 | -16751.00% | 488.00% | -377.00% | 11.17% | 0.60 | 23.02% | 0.00% | 0.00% | 36.04% | 50.37 | 8.72 | 2.65 | 1.65 |
| MRUS | Merus N.V. | $90.00 | 6.83B | -61% | -76% | — | -87% | -13.74 | 4.57 | 84.83 | -9.34 | -117.77 | 4.58 | 37.15% | -752.96% | -595.93% | -42.88% | -391.57% | -34.71% | 0.02 | — | 6.54 | 6.22 | 1.09 | 1167.00% | -1238.00% | 2826.00% | -6.34% | -2.13 | -279.56% | 0.00% | 0.00% | 3.06% | -9.26 | -12.97 | 69.71 | 11.12 |
| MTSR | Metsera, Inc. | $70.50 | 7.43B | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -108.40% | 1345.61% | -67.48% | 0.03 | -1008.22 | 5.34 | 5.24 | 1.57 | 10947.00% | — | 18254.00% | — | -1.49 | 625.73% | — | 0.00% | — | — | — | — | — |
| PCVX | Vaxcyte, Inc. | $61.74 | 8.86B | — | — | — | — | -11.00 | 3.14 | — | -9.58 | -22.85 | 3.14 | 0.00% | — | — | -25.59% | -61.93% | -23.38% | 0.09 | — | 7.91 | 7.81 | -0.07 | 4816.00% | — | 4089.00% | -7.93% | -3.19 | -44.87% | 0.00% | 0.00% | 0.00% | -7.69 | -10.61 | — | 12.61 |
| RYTM | Rhythm Pharmaceuticals, I… | $92.73 | 6.19B | -37% | +215% | — | — | -31.39 | 44.36 | 32.51 | -33.22 | — | 46.13 | 89.73% | -101.19% | -106.41% | -129.46% | 96.50% | -45.05% | 0.03 | -9.33 | 4.41 | 3.92 | 0.29 | -2834.00% | 4583.00% | 241.00% | -1.89% | -1.09 | 58.61% | 0.09% | -2.70% | 0.09% | -30.13 | -49.60 | 30.48 | 13.65 |
About Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
- CEO
- James R. Porter
- Employees
- 162
- Beta
- 1.32
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $99.04) − 1 = — (DCF, example).